IVGastric & duodenal ulcer, mild & severe gastroesophageal reflux 40 mg/day. Short-term maintenance of haemostasis & prevention of recurrence in patients w/ acute hemorrhagic gastric or duodenal ulcer 80 mg as bolus infusion for 2-15 min followed by continuous IV infusion at 8 mg/hr for 3 days. Zollinger-Ellison syndrome & other pathological hypersecretory conditions Initially 80 mg daily dose. May be titrated up or down as needed using measurements of gastric acid secretion. Divide & give as bid for >80 mg daily dose. Rapid acid control Starting dose: Two 80 mg. Administer IV over 2-15 min. Patient w/ hepatic impairment 20 mg daily dose.
Discontinue treatment in case of a rise of liver enzymes. May mask symptoms of gastric malignancy & delay diagnosis. Co-administration w/ HIV PIs. Increased risk of osteoporosis-related fractures of the hip, wrist, or spine. Symptomatic & asymptomatic hypomagnesaemia. Subacute cutaneous lupus erythematosus. Stop treatment for at least 5 days before chromogranin A (CgA) measurements. Increased risk of GI infections caused by bacteria eg, Salmonella & Campylobacter. Long-term treatment (>1 yr). Severe liver impairment. Pregnancy & lactation.
May interfere w/ the absorption of azole antifungals eg, ketoconazole, itraconazole, posaconazole & erlotinib. Significant reduction in the bioavailability of HIV PIs. Increased INR & prothrombin time w/ warfarin or phenprocoumon. Increased MTX levels. Increased systemic exposure w/ CYP2C19 inhibitors. May reduce plasma conc w/ rifampicin & St. John's wort.
Sign Out
